These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 38817600)

  • 1. Immune checkpoints: new insights into the pathogenesis of thyroid eye disease.
    Shu X; Shao Y; Chen Y; Zeng C; Huang X; Wei R
    Front Immunol; 2024; 15():1392956. PubMed ID: 38817600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
    Wall JR; Lahooti H
    Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
    Wall JR; Lahooti H
    Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
    Fernando R; Caldera O; Smith TJ
    Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is There Evidence for IGF1R-Stimulating Abs in Graves' Orbitopathy Pathogenesis?
    Krieger CC; Neumann S; Gershengorn MC
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.
    Dik WA; Virakul S; van Steensel L
    Exp Eye Res; 2016 Jan; 142():83-91. PubMed ID: 26675405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.
    Krieger CC; Sui X; Kahaly GJ; Neumann S; Gershengorn MC
    J Clin Endocrinol Metab; 2022 Mar; 107(4):e1653-e1660. PubMed ID: 34788857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
    Girnita L; Smith TJ; Janssen JAMJL
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S1-S12. PubMed ID: 35167695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients.
    van Steensel L; Hooijkaas H; Paridaens D; van den Bosch WA; Kuijpers RW; Drexhage HA; van Hagen PM; Dik WA
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E944-53. PubMed ID: 22438231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathophysiology of thyroid eye disease.
    Shan SJ; Douglas RS
    J Neuroophthalmol; 2014 Jun; 34(2):177-85. PubMed ID: 24821101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential involvement of the bone marrow in experimental Graves' disease and thyroid eye disease.
    Gulbins A; Horstmann M; Keitsch S; Soddemann M; Wilker B; Wilson GC; Zeidan R; Hammer GD; Daser A; Bechrakis NE; Görtz GE; Eckstein A
    Front Endocrinol (Lausanne); 2023; 14():1252727. PubMed ID: 37810891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
    Smith TJ; Hegedüs L; Douglas RS
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid eye disease: From pathogenesis to targeted therapies.
    Yoon JS; Kikkawa DO
    Taiwan J Ophthalmol; 2022; 12(1):3-11. PubMed ID: 35399971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
    Morshed SA; Ma R; Latif R; Davies TF
    Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies.
    Khoo TK; Bahn RS
    Thyroid; 2007 Oct; 17(10):1013-8. PubMed ID: 17935483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy.
    Paik JS; Kim SE; Kim JH; Lee JY; Yang SW; Lee SB
    Immunobiology; 2020 Mar; 225(2):151902. PubMed ID: 31899052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TSHR Signaling Stimulates Proliferation Through PI3K/Akt and Induction of miR-146a and miR-155 in Thyroid Eye Disease Orbital Fibroblasts.
    Woeller CF; Roztocil E; Hammond C; Feldon SE
    Invest Ophthalmol Vis Sci; 2019 Oct; 60(13):4336-4345. PubMed ID: 31622470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
    Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.
    Gulbins A; Horstmann M; Daser A; Flögel U; Oeverhaus M; Bechrakis NE; Banga JP; Keitsch S; Wilker B; Krause G; Hammer GD; Spencer AG; Zeidan R; Eckstein A; Philipp S; Görtz GE
    Front Endocrinol (Lausanne); 2023; 14():1211473. PubMed ID: 37435490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of IGF-1R in the interaction between orbital fibroblasts and B lymphocytes: an implication for B lymphocyte depletion in the active inflammatory phase of thyroid-associated ophthalmopathy.
    Wang R; Song D; Zhong Y; Li H
    BMC Immunol; 2024 May; 25(1):31. PubMed ID: 38734625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.